MedCAD has secured FDA 510(k) clearance for its AccuStride system, a patient-specific surgical planning and guide solution for lower leg tibia and fibula procedures. The Texas-based company utilizes LPBF titanium for its surgical guides, which are manufactured in-house to support a 5-day delivery cycle for US-based clinical customers. CEO Nancy Hairston confirmed that this clearance expands the firm's existing portfolio, which already includes fixation plates and guides for cranial, trauma, and CMF applications. The system integrates CT-based anatomical modeling with custom-printed hardware to streamline orthopedic workflows.

This clearance places MedCAD in direct competition with established medical AM providers like Materialise, which has long dominated the patient-matched surgical guide market. By offering a comprehensive, localized workflow from CT scan to final titanium implant, MedCAD addresses the high cost of operating room time, where reducing surgery duration by even 1-3 hours yields significant financial ROI for hospital systems. The medical AM sector is currently shifting toward integrated software-hardware ecosystems that lock in clinical users through proprietary planning interfaces and rapid, localized manufacturing cycles.

MedCAD must now focus on scaling its clinical adoption and demonstrating consistent operational efficiency to compete with larger, global incumbents. For orthopedic surgeons, the value proposition lies in the reduction of surgical variability and the potential for improved patient outcomes through anatomically precise, LPBF-produced instrumentation. The long-term success of this business model depends on the integration of automated segmentation software to further reduce the planning burden on clinical staff.